Technical Analysis for ALIM - Alimera Sciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical ALIM trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
NR7 | Range Contraction | -4.44% | |
Lower Bollinger Band Touch | Weakness | -4.44% | |
Fell Below 20 DMA | Bearish | -10.73% | |
20 DMA Support | Bullish | -18.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
50 DMA Support | 1 day ago | |
1.5x Volume Pace | 1 day ago | |
Down 10% | 1 day ago | |
Down 1 ATR | 1 day ago | |
60 Minute Opening Range Breakdown | 2 days ago |
Get a Trading Assistant
- Earnings date: 02/24/2021
Alimera Sciences, Inc. Description
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Diseases Eye Organ Systems Disease Diabetes Ophthalmic Macular Degeneration Related Macular Degeneration Retina Diabetic Retinopathy Icos Macular Edema Blindness Vein Age Related Macular Degeneration Diabetic Macular Edema Pivotal Fluid Dynamics Glucocorticoids Corticosteroid Pregnanes Alimera Sciences Diketones Fluocinolone Psivida Retinal Vein Occlusion
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.79 |
52 Week Low | 2.8602 |
Average Volume | 68,927 |
200-Day Moving Average | 5.72 |
50-Day Moving Average | 7.01 |
20-Day Moving Average | 8.45 |
10-Day Moving Average | 8.25 |
Average True Range | 0.83 |
ADX | 34.71 |
+DI | 22.62 |
-DI | 28.14 |
Chandelier Exit (Long, 3 ATRs ) | 8.31 |
Chandelier Exit (Short, 3 ATRs ) | 9.28 |
Upper Bollinger Band | 9.56 |
Lower Bollinger Band | 7.34 |
Percent B (%b) | -0.01 |
BandWidth | 26.21 |
MACD Line | 0.22 |
MACD Signal Line | 0.45 |
MACD Histogram | -0.2344 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.97 | ||||
Resistance 3 (R3) | 8.98 | 8.44 | 8.70 | ||
Resistance 2 (R2) | 8.44 | 8.02 | 8.44 | 8.60 | |
Resistance 1 (R1) | 7.88 | 7.76 | 7.61 | 7.87 | 8.51 |
Pivot Point | 7.34 | 7.34 | 7.21 | 7.34 | 7.34 |
Support 1 (S1) | 6.78 | 6.92 | 6.51 | 6.77 | 6.13 |
Support 2 (S2) | 6.24 | 6.66 | 6.24 | 6.04 | |
Support 3 (S3) | 5.68 | 6.24 | 5.95 | ||
Support 4 (S4) | 5.67 |